GE Medical Systems has agreed to distribute a preclinical optical molecular imaging system made by Advanced Research Technologies. The deal grants GE exclusive worldwide rights to distribute the system, called SAMITM, which is designed for use in the R&D
GE Medical Systems has agreed to distribute a preclinical optical molecular imaging system made by Advanced Research Technologies. The deal grants GE exclusive worldwide rights to distribute the system, called SAMITM, which is designed for use in the R&D of therapeutic and diagnostic drugs. The system is an optical fluorescence molecular imaging device designed to help pharmaceutical companies and research laboratories better understand disease and shorten the development cycle for new drugs. The technology is based on ART's proprietary time domain optical imaging technology, which noninvasively images tissue to reveal the biological distribution and concentration of fluorescence-labeled markers. GE holds an equity stake in the firm and is advising staff there on the development of clinical products based on the optical technology (SCAN 11/6/02).
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
The Reading Room Podcast: A Closer Look at Remote MRI Safety, Part 3
August 1st 2025In the third of a three-part podcast episode, Emanuel Kanal, M.D. and Tobias Gilk, MRSO, MRSE, discuss strategies for maintaining the integrity of time-out procedures and communication with remote MRI scanning.
The Reading Room Podcast: A Closer Look at Remote MRI Safety, Part 2
August 1st 2025In the second of a multi-part podcast episode, Emanuel Kanal, M.D. and Tobias Gilk, MRSO, MRSE, share their perspectives on remote MRI safety protocols for ensuring screening accuracy and adherence to conditional implant guidelines as well as a rapid and effective response to adverse events.
Twenty Years of CT Colonography for Colorectal Cancer Screening: What the Research Reveals
August 1st 2025Computed tomography colonography (CTC) demonstrated a 91.6 percent positive predictive value (PPV) for polyps > 6 mm, according to new research involving over 9,000 patients who underwent CTC for primary asymptomatic colorectal cancer screening.